Skip to main content

Fiscal Wizard · Single-issue tearsheet

LFCR / Jun 22, 2026 Run #7612

LFCR

Lifecore Biomedical, Inc.

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Composite verdict

F 19.2 / 100
Bearish setup · Reversal 7 drivers · 7 gates blocking
  • MACD Signal Cross
  • Parabolic SAR Flip
  • Accumulation/Distribution Line
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 53rd of 85 in Drug Manufacturers - Specialty & Generic

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 17 signals100% Bear
Momentum Bearish 19Mean-reversion Bearish 38

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

34.6 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Days Sales Outstanding 100
Free Cash Flow Yield 0
Inventory Turnover 100
EPS Growth (YoY) 0
Revenue Growth (YoY) 100
Return on Equity 25

Technicals Bearish

3.8 / 100

Bearish setup leads (MACD Signal Cross, Parabolic SAR Flip, Accumulation/Distribution Line); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Parabolic SAR Flip 12
MACD Signal Cross 12
Declining Volume 16

Risk Gates

7 blocking 5 caution

7 guards active, 22 signals gated.

Debt-to-Assets Blocking

High debt-to-assets blocks bullish signals — balance-sheet leverage risk.

Debt-to-Equity Blocking

High debt-to-equity blocks bullish signals — leverage risk.

Interest Coverage Blocking

Weak interest coverage blocks bullish signals — debt-service risk.

LT Debt-to-Equity Blocking

High long-term D/E blocks bullish signals — structural-leverage risk.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for LFCR.